Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als symbols : Qnrx save search
Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton SyndromeQuoin Anticipates Initiating Clinical Testing in Q2 2022
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: -2.34%
H: 2.4%
C: 0.0%
qrx003 als test set submission
Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome
Published: 2022-03-15 (Crawled : 13:00) - globenewswire.com
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: -2.34%
H: 2.4%
C: 0.0%
qrx003 als set submission syndros
Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton SyndromeFirst Step in Development Process of QRX003 for the EU
Published: 2022-03-10 (Crawled : 23:00) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: -4.13%
H: 25.0%
C: 19.27%
qrx003 ema als set
Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
Published: 2022-03-01 (Crawled : 13:30) - globenewswire.com
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: 5.71%
H: 12.61%
C: 5.41%
qrx003 als distribution set syndros
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: 2.8%
H: 0.0%
C: -7.48%
qrx003 als distribution set syndros
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
Published: 2022-02-10 (Crawled : 13:30) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: 0.7%
H: 5.56%
C: 0.0%
qrx003 als distribution set syndros
Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy
Published: 2022-02-08 (Crawled : 15:30) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: -1.41%
H: 2.52%
C: 1.43%
als liver
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome
Published: 2022-01-26 (Crawled : 16:00) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: -1.45%
H: 2.94%
C: -5.15%
qrx003 als distribution set syndros
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton SyndromeOrpharm Gains Exclusive Rights to Commercialize QRX003 in Russia and CIS
Published: 2021-12-15 (Crawled : 15:30) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K
|
Professional, Scientific, and T...
|
| O: 60.06%
H: 1.18%
C: -45.38%
qrx003 als russia distribution
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.